UNSPSC 51282105: Latamoxef or moxalactam

This classification denotes a beta-lactam antibiotic with the molecular formula C20H20N6O9S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VUF6C936Z3, chemically known as 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (6r-(6alpha,7alpha,7(s*)))- but generally known as latamoxef, which bears US NIH Compound Identifier 47499.

UNSPSC 51282105 Latamoxef or moxalactam is a Commodity code that state and local health agencies use to procure pharmaceutical products, though the recent opportunities block shows minimal activity specifically tagged to this antibiotic code. The two posted records—an Illinois Department of Public Health piggyback pharmaceutical warehouse contract and a Seminole County, Florida procurement for naloxone and drug deactivation systems—are unrelated to latamoxef or moxalactam. The Illinois solicitation (26482DPHPREPDB53392) covers Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets supplied through the MMCAP Infuse consortium to Chartwell Rx LLC, while the Seminole County IFB (IFB60459723LAS) addresses community health supply of naloxone and safe drug deactivation systems. Neither represents the antibiotic scope this code nominally covers, signaling that state and local procurement under 51282105 sees little current visible activity in public records.

The geographic distribution and issuing-body mix are likewise constrained by the source. Florida and Illinois appear in the recent records, but both opportunities are misaligned with the code's intended scope. The Illinois award to Chartwell Rx LLC carried a three-year term and a total value of $2.999999 million, while the Seminole County contract specified annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems on a two-year initial term with one-year renewal option. No open solicitations matching latamoxef or moxalactam procurement are present in the source, and pursuit decisions under this code should be informed by the finding that state and local procurement activity tagged to it does not align with the antibiotic's actual use case.